JP2022523320A5 - - Google Patents

Info

Publication number
JP2022523320A5
JP2022523320A5 JP2021544320A JP2021544320A JP2022523320A5 JP 2022523320 A5 JP2022523320 A5 JP 2022523320A5 JP 2021544320 A JP2021544320 A JP 2021544320A JP 2021544320 A JP2021544320 A JP 2021544320A JP 2022523320 A5 JP2022523320 A5 JP 2022523320A5
Authority
JP
Japan
Prior art keywords
mir
nucleic acid
oligonucleotide
pharmaceutical composition
capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015638 external-priority patent/WO2020160121A1/en
Publication of JP2022523320A publication Critical patent/JP2022523320A/ja
Publication of JP2022523320A5 publication Critical patent/JP2022523320A5/ja
Pending legal-status Critical Current

Links

JP2021544320A 2019-01-29 2020-01-29 加齢黄斑変性の処置のためのオリゴヌクレオチドおよび方法 Pending JP2022523320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798048P 2019-01-29 2019-01-29
US62/798,048 2019-01-29
PCT/US2020/015638 WO2020160121A1 (en) 2019-01-29 2020-01-29 Oligonucleotides and methods for the treatment of age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2022523320A JP2022523320A (ja) 2022-04-22
JP2022523320A5 true JP2022523320A5 (https=) 2023-02-06

Family

ID=71840609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544320A Pending JP2022523320A (ja) 2019-01-29 2020-01-29 加齢黄斑変性の処置のためのオリゴヌクレオチドおよび方法

Country Status (4)

Country Link
US (1) US20220195428A1 (https=)
EP (1) EP3918072A4 (https=)
JP (1) JP2022523320A (https=)
WO (1) WO2020160121A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4331606A4 (en) * 2021-04-30 2025-05-07 Kyoto University PREVENTION OR TREATMENT OF MYOPATHY USING A MIR-33B INHIBITOR

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
EP1791567B1 (en) * 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
DE602005024015D1 (de) * 2004-08-23 2010-11-18 Alnylam Pharmaceuticals Inc Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren
US20110130440A1 (en) * 2008-03-26 2011-06-02 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
US8057295B2 (en) * 2008-11-10 2011-11-15 Wms Gaming Inc. Wagering game having award group selection feature
US20110281933A1 (en) * 2010-05-13 2011-11-17 Saint Louis University Methods and compositions for the management of cardiovascular disease with oligonucleotides
CA2808889A1 (en) * 2010-08-27 2012-03-01 New York University Mir-33 inhibitors and uses thereof
US9241950B2 (en) * 2011-04-28 2016-01-26 New York University MiR-33 inhibitors and uses thereof to decrease inflammation
US20120301439A1 (en) * 2011-05-24 2012-11-29 Washington University Inhibition of choroidal neovascularization
US20140363469A1 (en) * 2012-01-19 2014-12-11 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
US11046955B2 (en) * 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
GB201607797D0 (en) * 2016-05-04 2016-06-15 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Glaucoma therapy
US10426817B2 (en) * 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics

Similar Documents

Publication Publication Date Title
JP2022518504A5 (https=)
IL273261B2 (en) Adeno-associated virus variant capsids and methods of using them
RU2018140499A (ru) Способы и композиции для лечения хореи гентингтона
JP2022508182A5 (https=)
JP2020019772A5 (https=)
JP2020533959A5 (https=)
JP2021512649A5 (https=)
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
JP2017510298A5 (https=)
JP2022531809A5 (https=)
JP2007507223A5 (https=)
JP2022505381A5 (https=)
JP6966463B2 (ja) 組換えウイルス産物及びｄｕｘ４エクソンスキッピングを誘導するための方法
JP2023514242A5 (https=)
JP2023534037A5 (https=)
JP2024508696A5 (https=)
JP2023537358A5 (https=)
JP2023537980A5 (https=)
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
JP2023500793A5 (https=)
JP2023553005A5 (https=)
JP2023541443A5 (https=)
WO2025038430A1 (en) Aav capsid variants and uses thereof
US20210108197A1 (en) Shrna expression cassette, polynucleotide sequence carrying same, and application thereof
JP2025513785A5 (https=)